방법 비교

	짝을 이룬 3상 임상시험	적응적 3상 임상시험
분야	역학	역학
계열	Process / pipeline	Process / pipeline
기원 연도	Mid-20th century (matching in RCTs formalized ~1950s–1970s)	1969–2019 (sequential testing roots ~1969; formal adaptive design guidance 2010–2019)
창시자	Fisher, R. A. (matching principles); adapted into confirmatory trial design over mid-20th century	Methodological foundations by Armitage et al. (1969); modern adaptive framework codified by FDA and ICH guidance (2010s)
유형	Controlled confirmatory clinical trial with matching	Interventional confirmatory clinical trial with pre-specified interim adaptations
원전	Rothman, K. J., Greenland, S., & Lash, T. L. (2008). Modern Epidemiology (3rd ed.). Lippincott Williams & Wilkins. ISBN: 978-0781755641	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2019). ICH E9(R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials. ICH Harmonised Guideline.
별칭	matched controlled Phase III trial, Phase III matched-pair trial, matched confirmatory trial, matched late-phase RCT	adaptive confirmatory trial, seamless Phase II/III adaptive trial, adaptive pivotal trial, adaptive design Phase III
관련	5	6
요약	A matched Phase III clinical trial is a confirmatory, late-stage controlled study in which each participant assigned to the experimental treatment is paired with one or more controls who share key prognostic characteristics — such as age, disease stage, or comorbidities — before treatment allocation. By ensuring baseline comparability at the level of matched pairs, the design reduces confounding and improves statistical efficiency in settings where simple randomization alone may produce imbalanced groups or where full randomization is logistically or ethically constrained.	An adaptive Phase III clinical trial is a confirmatory randomized controlled trial that incorporates pre-specified rules allowing modifications to the trial design — such as sample size re-estimation, dose selection, or population enrichment — based on accumulating interim data, while preserving the Type I error rate. It sits at the top of the evidence hierarchy and is used to obtain regulatory approval of new interventions.